• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Novel synthetic plasmid and doggybone? DNA vaccines induce neutralizing antibodies and provide protection from lethal influenza challenge in mice

tetano

Editor, Senior Moderator
Hum Vaccin Immunother. 2015 Jun 19:0. [Epub ahead of print]
[h=1]Novel synthetic plasmid and doggybone? DNA vaccines induce neutralizing antibodies and provide protection from lethal influenza challenge in mice.[/h] Scott VL[SUP]1[/SUP], Patel A, Villarreal DO, Hensley SE, Ragwan E, Yan J, Sardesai NY, Rothwell PJ, Extance JP, Caproni LJ, Weiner DB.
[h=3]Author information[/h]

[h=3]Abstract[/h] Nucleic acid-based vaccines (NAVs) are a promising alternative to conventional influenza vaccines with the potential to increase influenza vaccine availability due to their simplicity in design and rapid speed of production. NAVs can also target multiple influenza antigens and control flu variants. Traditionally NAVs have been DNA plasmids however, we are continuing to explore new methods that may enhance vaccine efficacy. Recently new focus has been on RNA cassettes as NAVs. RNA vaccines combine conceptual advantages in that they focus on delivery of only the coding cassette. However, RNA vaccines have a short half-life and cause interferon-induced fevers. Here we describe a new NAV approach where we study delivery of a linear DNA cassette [Doggybone? linear closed DNA [(dbDNA?)] produced by an enzymatic process that yields an antigen expression cassette comprising a promoter, DNA antigen, poly A tail, and telomeric ends. This focused approach has many of the advantages of plasmid DNA as well as a minimal cassette size similar to RNA strategies. For this study, we characterized the specific CD4[SUP]+[/SUP] and CD8[SUP]+[/SUP]T cell responses and determined the hemagglutination inhibition (HI) titers induced by dbDNA? and compared the responses with those of an optimized plasmid DNA (pDNA) vaccine encoding the same H1N1 influenza A/PR/8/34 HA gene. Immunizations with the constructs resulted in similar humoral and cellular immune responses. Both constructs induced high-titer HI antibodies and fully protected animals from lethal viral challenge. The data obtained from this study provides important validation for further development of novel vector approaches.


[h=4]KEYWORDS:[/h] Doggybone; Influenza; Linear DNA; Neutralization; Plasmid DNA

PMID: 26091432 [PubMed - as supplied by publisher]
 
Back
Top Bottom